Kim Edmonds and colleagues stress the importance of identifying the symptoms of adverse events in patients being treated for metastatic melanoma and outline ways nurses can advise and support this client group
The advice presented in this article reflects the consensus opinion of research and oncology nurses and a clinical trials practitioner involved in managing patients with metastatic malignant melanoma. The nurses met in September 2011 to discuss the side effects they have encountered when patients are taking vemurafenib and to share best practice on how to manage them. As vemurafenib becomes available in clinics following its recent launch in Europe, nurses will need to anticipate and manage the potential adverse events to ensure patients receive the most effective treatment.
Cancer Nursing Practice. 11, 5, 14-21. doi: 10.7748/cnp2012.06.11.5.14.c9148
Correspondence Conflict of interestSuccinct Healthcare Communications set up the meeting in September 2011 and provided medical writing support, both of which were funded by Roche Products Ltd. Editorial control was retained by the authors
Peer reviewThis article has been subject to double blind peer review
or
Alternatively, you can purchase access to this article for the next seven days. Buy now
Are you a student? Our student subscription has content especially for you.
Find out more
